SCHEMBL12072452

SCHEMBL12072452

CC(C)(C)OC(=O)Nc1ccc(Oc2ncnc(N)c2N)c2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.43
KDR P35968 11/20 0.42
EGFR P00533 3/20 0.41
ABL1 P00519 3/20 0.41
PIK3CD O00329 2/20 0.41
PIK3CA P42336 2/20 0.41
PIK3CG P48736 2/20 0.41
PRKDC P78527 2/20 0.41
BACE1 P56817 1/20 0.41
PI4KB Q9UBF8 1/20 0.41
FGFR4 P22455 1/20 0.41
HCK P08631 3/20 0.40
SRC P12931 3/20 0.40
MAPK14 Q16539 3/20 0.40
MAPK12 P53778 2/20 0.40
PIK3CB P42338 1/20 0.40
MTOR P42345 1/20 0.40
EPHB4 P54760 1/20 0.40
AURKA O14965 2/20 0.38
LCK P06239 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12072463 0.86 SMN1; SMN2 (0.52) MAP4K4KDREGFRABL1PIK3CD
SCHEMBL2936138 0.85 BRAF (0.43) KDRSRCMAPK14MAPK12AURKA
SCHEMBL4689617 0.82 AAK1 (0.44) KDRAURKALCKTEKAURKB
SCHEMBL15021980 0.81 HCK (0.57) HCKSRCMAPK14MAPK12BRAF
SCHEMBL15492470 0.79 MAPK14 (0.48) MAP4K4KDREGFRFGFR4SRC
SCHEMBL12072470 0.78 GPR119 (0.45) KDREGFRFGFR4HCKSRC
SCHEMBL12596427 0.76 MAPK14 (0.50) HCKSRCMAPK14MAPK12
SCHEMBL12847422 0.76 SRC (0.41) MAP4K4KDREGFRABL1PIK3CD
SCHEMBL2935085 0.76 BRAF (0.40) KDRHCKSRCMAPK14MAPK12
SCHEMBL29662432 0.76 BRAF (0.40) KDRHCKSRCMAPK14MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10358445-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2019-07-23 US disclosed
US-20180201611-A1 Respiratory formulations and compounds for use therein RESPIVERT LTD. (GB) 2018-07-19 US disclosed
US-20180201611-A1 Respiratory formulations and compounds for use therein RESPIVERT LTD. (GB) 2018-07-19 US disclosed
EP-2582700-B1 RESPIRATORY FORMULATIONS CONTAINING P38 MAPK INHIBITORS RESPIVERT LTD (GB) 2016-11-02 EP disclosed
US-8933228-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2015-01-13 US disclosed
US-8933228-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2015-01-13 US disclosed
US-20130156826-A1 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN RESPIVERT LIMITED (GB) 2013-06-20 US disclosed
US-20130156826-A1 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN RESPIVERT LIMITED (GB) 2013-06-20 US disclosed
WO-2011158044-A2 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN RESPIVERT LIMITED (GB) 2011-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130156826-A1 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN TSLP, CCL11, RORB MAP4K4 3546/4885KDR 4107/4885EGFR 2562/4885
US-10358445-B2 Respiratory formulations and compounds for use therein TSLP, CCL11, RORB MAP4K4 3546/4885KDR 4107/4885EGFR 2562/4885
US-20180201611-A1 Respiratory formulations and compounds for use therein TSLP, CCL11, RORB MAP4K4 3546/4885KDR 4107/4885EGFR 2562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.